Comparison · NCT02021318-fb359505
Roxadustat vs Darbepoetin Alfa: Number of Participants With End Stage Renal Disease (ESRD)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Download JSON
Cite this record
ConductScience Library. Roxadustat vs Darbepoetin Alfa: Number of Participants With End Stage Renal Disease (ESRD). Trial comparisons, record NCT02021318-fb359505. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02021318-fb359505
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.342 | 0.292 | 0.395 | wilson | |
| Risk in group 2 | 0.366 | 0.313 | 0.423 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0248 | -0.1 | 0.0505 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.932 | 0.753 | 1.15 | log | |
| Odds ratio, group 1 over group 2 | 0.897 | 0.644 | 1.25 | log | |
| Number needed to treat, for one fewer participant with the outcome on Roxadustat than on Darbepoetin Alfa | 40.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Roxadustat | Participants received roxadustat orally according to the tiered weight-based approach, with starting dose of 70 mg given TIW to participants weighing between 45 kg up to 70 kg and 100 mg given TIW to participants weighing more than 70 kg up to 160 kg. Dose-titration was performed based upon regular measurement of Hb levels until participants achieved central Hb value of \>= 11.0 g/dL and Hb increase from baseline of \>= 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received roxadustat for up to a maximum of 104 weeks. | 110 | 322 | OG000 |
| Group 2 | Darbepoetin Alfa | Participants received initial dose of darbepoetin alfa based upon the weight \[either 0.45 mcg/kg of body weight, as a single subcutaneous or IV injection once weekly or 0.75 mcg/kg of body weight, as a single subcutaneous injection once every 2 weeks\] as per EU SmPC along with IV iron supplementation according to the standard of care. Dose-adjustment was performed based upon regular measurement of Hb levels until participants achieved central Hb value of \>= 11.0 g/dL and Hb increase from baseline of \>= 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which darbepoetin alfa dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL. Participants received darbepoetin alfa for up to a maximum of 104 weeks. | 107 | 292 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With End Stage Renal Disease (ESRD)
- Description
Occurrence of end stage renal disease during the study (i.e from day 1 up to the end of study) was defined as at least one of the following: underwent \>30 days dialysis therapy, received kidney transplant, planned kidney transplant, physician recommended renal replacement therapy and participant refused therapy, began dialysis and died \< 30 days later.
- Time frame
- Baseline up to EOS (up to week 108)
- Population
- The analysis population was the FAS.
Source ClinicalTrials.gov
Trial
- Title
- Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa
- NCT number
- NCT02021318
- Phases
- PHASE3
- Conditions
- Anemia in Chronic Kidney Disease in Non-dialysis Patients
- Interventions
- Roxadustat, Darbepoetin alfa
- Lead sponsor
- Astellas Pharma Europe B.V.
- Results first posted
- 2021-03-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02021318?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02021318-fb359505